RecruitingPhase 3NCT07190209
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sponsor: Sanofi
Chandler, AZ · Phoenix, AZ · Surprise, AZ · +72 more sites